Regeneron Pharmaceuticals dividend and valuation
Valuation
Regeneron Pharmaceuticals paid $3.70 per share in dividends over the last 12 months (yield 0.4%). Next ex-dividend date: November 20, 2026. The P/E ratio is 21.1. The average price target of 27 analysts is $984.96.
Data as of November 16, 2026
Regeneron Pharmaceuticals compared with similar companies
Regeneron Pharmaceuticals's P/E (trailing 12 months): 21.1, −39% against the median of a group of 7 similar companies (34.7).
| Metric | Regeneron Pharmaceuticals | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 21.1 | 34.7 | 27.2 – 49.4 | Low |
| Forward P/E | 13.5 | 21.1 | 13.9 – 31.3 | Low |
| EV/EBITDA | 15.8 | 22.8 | 17.1 – 26.3 | Low |
| Price/book | 2.86 | 7.20 | 5.33 – 14.4 | Low |
| Price/sales | 5.85 | 10.4 | 6.19 – 16.9 | Low |
| Gross margin | 46.7% | 56.0% | 23.4% – 80.8% | Middle |
| Operating margin | 30.4% | 19.5% | -61.2% – 32.1% | Middle |
| Net margin | 28.5% | 13.9% | 0.0% – 29.6% | Middle |
| ROE | 14.9% | 12.1% | -21.5% – 19.6% | Middle |
| Debt/equity | 0.08 | 0.35 | 0.05 – 0.73 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Regeneron Pharmaceuticals: valuation over time
On the latest fiscal year's earnings (2025), Regeneron Pharmaceuticals's P/E today is 23.0, above the median of its last 10 fiscal years (18.7; between 8.77 and 47.7 from 2016 to 2025). Relative to earnings, the stock costs more than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| 2025 | $771.87 | $41.48 | 18.6 | $3.52 | 0.5% |
| 2024 | $712.33 | $38.34 | 18.6 | — | — |
| 2023 | $878.29 | $34.77 | 25.3 | — | — |
| 2022 | $721.49 | $38.22 | 18.9 | — | — |
| 2021 | $631.52 | $71.97 | 8.77 | — | — |
| 2020 | $483.11 | $30.52 | 15.8 | — | — |
| 2019 | $375.48 | $18.46 | 20.3 | — | — |
| 2018 | $373.50 | $21.29 | 17.5 | — | — |
| 2017 | $375.96 | $10.34 | 36.4 | — | — |
| 2016 | $367.09 | $7.70 | 47.7 | — | — |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $98.84B
- Enterprise value
- $89.29B
- PEG
- 1.16
- EV/revenue
- 5.28
Profitability and growth
- ROA
- 7.6%
- ROIC
- 16.3%
- Revenue growth (year over year)
- 36.3%
- Earnings growth (year over year)
- 35.5%
Financial health
- Total cash
- $9.3B
- Total debt
- $2.71B
- Current ratio
- 3.35
- Quick ratio
- 2.72
- Altman Z-Score
- 6.44
- Piotroski F-Score
- 6.00
Dividends
- Annual dividend per share
- $3.70
- Dividend yield
- 0.4%
- Payout ratio
- 8.2%
- Ex-dividend date
- November 20, 2026
Analysts and estimates
- Average price target
- $984.96
- Median price target
- $997.00
- High price target
- $1,175.00
- Low price target
- $812.00
- Analysts with a price target
- 27
- Consensus
- Buy
- Forward EPS
- $70.84
- EPS estimate, current year
- $69.01
Shares and trading
- Beta
- 0.10
- Average volume
- 797.86K
- Shares outstanding
- 101.63M
- Float
- 96.35M
- Institutional ownership
- 92.6%
- Insider ownership
- 2.2%
- Short interest (% of float)
- 2.3%
- Short ratio (days)
- 2.93
